ArticleHaematologica2022

Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?

Mehdi HamadaniPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.